Aurobindo Pharma Ltd.‘s revenue in Q2FY23 fell 3% to ₹ 5,739 crores. Consolidated Profit came at ₹ 409 crores showcasing a 41%
Categories
Health Care
Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Transcript
Biocon Limited (NSE: BIOCON) Q2 FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Saurabh Paliwal -- Head, Investor Relations Kiran Mazumdar
JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Q2 FY23 Earnings Concall Transcript
JB Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Q2 FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Jason D'Souza -- Vice President of Investor Relations Nikhil Chopra -- Chief
Glenmark Pharmaceuticals Limited (GLENMARK) Q2 FY23 Earnings Concall Transcript
Glenmark Pharmaceuticals Limited (NSE: GLENMARK) Q2 FY23 Earnings Concall dated Nov. 13, 2022 Corporate Participants: Utkarsh Gandhi -- General Manager - Investor Relations Brendan
Aurobindo Pharma Limited (AUROPHARMA) Q2 FY23 Earnings Concall Transcript
Aurobindo Pharma Limited (NSE: AUROPHARMA) Q2 FY23 Earnings Concall dated Nov. 13, 2022 Corporate Participants: Deepti Thakur -- Investor Relations Santhanam Subramanian -- Chief Financial Officer
Gufic Biosciences Limited (GUFICBIO) Q1 FY23 Earnings Concall
Gufic Biosciences Limited (NSE:GUFICBIO) Q2 FY23 Earnings Concall dated Nov.13, 2022 Corporate Participants: Ami Naresh Shah -- Company Secretary and Compliance Officer Avik Das -- Investor
Alembic Pharmaceuticals Limited (APLLTD) Q2 FY23 Earnings Concall Transcript
Alembic Pharmaceuticals Limited (NSE:APLLTD) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Raj Kumar Baheti -- Director - Finance and Chief Financial
MedPlus Health Services Ltd (MEDPLUS) Q2 FY23 Earnings Concall Transcript
MedPlus Health Services Ltd (NSE:MEDPLUS) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Gangadi Madhukar Reddy -- Managing Director and Chief Executive Officer Prasad
Healthcare Global Enterprises Ltd (HCG) Q2 FY22 Earnings Concall Transcript
Healthcare Global Enterprises Ltd (NSE:HCG) Q2 FY22 Earnings Concall dated Nov. 11, 2022 Corporate Participants: B.S. Ajai Kumar -- Executive Chairman Raj
Apollo Hospitals Enterprise Limited (APOLLOHOSP) Q2 FY23 Earnings Concall Transcript
Apollo Hospitals Enterprise Limited (NSE: APOLLOHOSP) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Suneeta Reddy -- Managing Director Krishnan
Krishna Institute of Medical Sciences Limited (KIMS) Q2 FY23 Earnings Concall Transcript
Krishna Institute of Medical Sciences Limited (NSE:KIMS) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Bhaskar Rao Bollineni -- Founder
Dishman Carbogen Amcis Ltd (DCAL) Q2 FY22 Earnings Concall Transcript
Dishman Carbogen Amcis Ltd (NSE: DCAL) Q2 FY22 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Arpit Vyas -- Global Managing Director Pascal Villemagne -- Vice
Alkem Laboratories Ltd (ALKEM) Q2 FY23 Earnings Concall Transcript
Alkem Laboratories Ltd (NSE:ALKEM) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Amit Kumar Khandelia -- Assistant Vice President, Finance
Supriya Lifescience Ltd (SUPRIYA) Q2 FY23 Earnings Concall Transcript
Supriya Lifescience Ltd (NSE:SUPRIYA) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Rasika Sawant -- Investor Relation Partner Satish Wagh
Narayana Hrudayalaya Limited (NH) Q2 FY23 Earnings Concall Transcript
Narayana Hrudayalaya Limited (NSE:NH) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Unidentified Speaker -- Emmanuel Rupert -- Managing Director
Sequent Scientific Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/-5pgj3qU44c Key highlights from Sequent Scientific Limited (SEQUENT) Q2 FY23 Earnings Concall Q&A Highlights: [00:17:40] Rishab Jain asked about Tineta Pharma acquisition,
Krsnaa Diagnostics Ltd (KRSNAA) Q2 FY23 Earnings Concall Transcript
Krsnaa Diagnostics Ltd (NSE:KRSNAA) Q2 FY23 Earnings Concall dated Nov. 10, 2022 Corporate Participants: Yash Prithviraj Mutha C.A. -- Whole-Time Director Pawan
Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights
https://youtu.be/lAaNZKEvjOc Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:43] Rahul Agarwal with Incred Capital enquired
Lupin Q2FY23 results out: Net profit rises more than 100%
Shares of Lupin gained as much as 8 percent in early trading on Thursday after the company returned to profitability during the
Cipla Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from Cipla Limited (CIPLA) Q2 FY23 Earnings Concall Management Update: [00:02:21] CIPLA reported the highest quarterly revenue historically of INR5,829
Solara Active Pharma Sciences Limited (SOLARA) Q2 FY23 Earnings Concall Transcript
Solara Active Pharma Sciences Limited (NSE:SOLARA) Q2 FY23 Earnings Concall dated Nov. 09, 2022 Corporate Participants: Abhishek Singhal -- Investor Relations Jithesh Devendra -- Managing Director